Infliximab for the Treatment of Hidradenitis Suppurativa
- 1 June 2007
- journal article
- Published by S. Karger AG in Dermatology
- Vol. 215 (1), 41-44
- https://doi.org/10.1159/000102032
Abstract
Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective. To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms of hidradenitis suppurativa. A retrospective study in a group of 6 patients who received treatment with infliximab for hidradenitis suppurativa, in the Dermatology Department of the University Hospital of Puerto Real in the last year. The dose was 5-10 mg/kg at weeks 0, 2 and 6, followed by a maintenance dose every 4 weeks. Subjective and objective efficacy was assessed before and after each treatment session. All patients experienced improvement in subjective symptoms after the initial dose. A decrease in exudation, the size and number of lesions and less development of fistulous tracts were observed. The patients were followed up during 6 months. Treatment was generally well tolerated and there was only one mild reaction to the infusion in the form of headache. No patient required treatment discontinuation due to adverse effects. Infliximab was shown to be an effective therapeutic alternative for severe extensive forms of hidradenitis suppurativa when it is used as monotherapy.Keywords
This publication has 17 references indexed in Scilit:
- Bacteraemia in Patients with Hidradenitis Suppurativa Undergoing Carbon Dioxide Laser Surgery: Detection and Quantification of Bacteria by Lysis-FiltrationDermatology, 2006
- Anti-Tumor Necrosis Factor Alpha-Induced Psoriasiform Eruptions: Three Further Cases and Current OverviewDermatology, 2006
- Long-term infliximab for severe hidradenitis suppurativaBritish Journal of Dermatology, 2006
- Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the LiteratureDermatology, 2005
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis & Rheumatism, 2005
- Infliximab-Induced VitiligoDermatology, 2004
- Severe Hidradenitis Suppurativa Treated With Infliximab InfusionArchives of Dermatology, 2003
- Infliximab for the treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2003
- Probable association between hidradenitis suppurativa and Crohn's disease: Significance of epithelioid granulomaBritish Journal of Surgery, 1997
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994